TOPICS: COVID-19Videos

 

The flu virus spreads when people breathe in respiratory particles from the sneezes and coughs of someone who is infected, or when they touch surfaces which are contaminated with the virus. The best advice to avoid the flu is to not be in crowded areas with poor ventilation, not go to work places or schools where others are infected, and to wash your hands regularly. This year, the southern hemisphere’s flu season coincided with the start of the COVID-19 pandemic, which had a dramatic impact on cases of influenza. The measures introduced to prevent the spread of COVID-19, with human contact reduced to almost zero, increasing wearing of surgical and cloth masks and the increase in regular hand washing, meant there were virtually no flu cases.

Lockdown wiped out the flu season in the South

Seasonal flu kills about 0.1% of people it infects, but since it spreads easily, it is estimated to kill on average 389,000 a year (about 2% of all annual respiratory deaths). Of these deaths, 67% were among people aged 65 years or older.

South Africa sees around 11,000 flu deaths every year. To keep track of cases, its National Institute for Communicable Diseases (NICD) undertakes rigorous flu surveillance, involving random laboratory screening. Usually, this would identify about 1,000 cases of flu, but by the end of March, the institute recorded only a single case.

A similar pattern has been observed elsewhere. For instance, a study of flu activity during COVID-19 showed that between April and July 2020, only 33 cases were found among 60,031 specimens tested in Australia, 12 in 21,178 specimens in Chile, and six in 2,098 in South Africa – a total of 51 influenza positive specimens out of 83,307 tested (0.06%). By contrast, during the same months in 2017–2019, 24,512 specimens tested positive for influenza among 178,690 across these three countries. That’s 13.7% - so significantly higher than this year.

The best advice to avoid the flu is to not be in crowded areas with poor ventilation, not go to work places or schools where others are infected, and to wash your hands regularly.

How bad will the northern hemisphere’s flu season be?

The COVID-19 lockdown also had a positive effect on the northern hemisphere’s flu season, which was tailing off at the start of the pandemic. In the United States, there was a 98% decrease in flu sample specimens testing positive, from 19.34% in September to February, down to just 0.33% between March and May. 

In many countries with unusually low numbers of flu cases, reduced testing may initially have contributed, But when public health officials and clinicians made renewed efforts to identify adequate numbers of samples to test, they still found little trace of the influenza virus.

So, what does this mean for the northern hemisphere over the coming months? 

The main difference now, say scientists, is that whereas countries were shutting down at the start of the southern flu season, they are now opening up – including re-opening schools, which is a major contributor to the spread of flu. It’s true that life has not totally gone back to the ease of movement of pre-pandemic days. In Spain, for example, measures taken to reduce the spread of COVID-19 in schools, such as smaller class sizes, frequent hand-washing and requiring children over the age of six years to wear masks all day, could also slow the spread of flu.

But countries are implementing more varied and complex restrictions around COVID-19 than they did back at the start of the pandemic, meaning many people have far more social contact now than they did during lockdown. Even with continued guidance to maintain social distancing, wear masks and wash hands, pandemic fatigue could mean that people are tiring of these measures, or taking them less seriously than when COVID-19 first emerged.

Why the flu vaccine is more important than ever

The prospect of the northern hemisphere flu season swamping countries with influenza cases as well as COVID-19 is grim; co-infection with both respiratory viruses could be deadly. Many countries are already seeing a second wave of the coronavirus cases and the additional burden of caring for people with flu could be disastrous. Plus, people with flu symptoms will need testing to rule out COVID-19, and testing systems are already under strain almost everywhere.

Also, there could be an unexpected downside to fewer cases of flu: every year, researchers study circulating influenza viruses to guide the composition of the flu vaccine for the following year. Less circulating flu virus means it is harder to know which genetic variants have been most common, and are therefore most likely to be the dominating ones the following year. By the end of this month, flu experts will need to settle on the make-up of next year’s flu vaccine for the southern hemisphere. 

During these uncertain times, flu vaccinations will be more important than ever - especially for older people or those with underlying conditions. Because of this, flu vaccine manufacturers such GlaxoSmithKline and AstraZeneca are ramping up production for the 2020-21 season in northern countries. The US CDC is expected to produce up to 198 million doses - an increase of 20 million compared to last year. Similarly the UK is expanding the age groups eligible for a free flu shot among both children and adults.

We'd love to hear your feedback!

Related content

Interim analysis of the AstraZeneca/Oxford COVID-19 vaccine candidate – to which Gavi has secured access – suggests an efficacy of 62– 90%. Crucially, the vaccine can be administered and distributed using existing health care and supply chain…

Unlike PCR tests, which involve complex laboratory equipment and highly trained staff, lateral flow tests can be processed on the spot and return a result far quicker. But how exactly do they work, and could they really make a difference to the…

The two terms used to describe how well a drug or vaccine works are often used interchangeably, but they are not actually the same thing – here’s why.

COVID-19 vaccines are set to become the quickest vaccines in history to go from initial trials to rollout, but what lessons can we learn from its speedy predecessor: the Ebola vaccine?

The fight against COVID-19 has seen vaccine development move at record speed, with more than 170 different vaccines in trials. But how are they different from each other and how will they protect us against the disease?

Viral vector-based vaccines use a harmless virus to smuggle the instructions for making antigens from the disease-causing virus into cells, triggering protective immunity against it.

Protein subunit vaccines use fragments of protein from the disease-causing virus to trigger protective immunity against it.

Whole virus vaccines use a weakened or deactivated version of the disease-causing virus to trigger protective immunity against it.

Nucleic acid vaccines use genetic material from a disease-causing virus to trigger protective immunity against it.

Interim results suggesting that Pfizer/BioNTech’s COVID-19 vaccine provides more than a 90% efficacy, offers hope that immunisation can be effective against COVID-19. But the need to store this vaccine at “ultra cold” temperatures could pose…

Immunity triggered by exposure to the coronaviruses that cause the common cold could protect people, especially children, against the SARS-CoV-2 virus.

A successful vaccine produces the best possible immune response, whilst keeping side effects to a minimum. When adverse events following immunisation (AEFIs) do occur, it is important that they are reported, especially if they are serious, even…

An interim analysis of the Pfizer/BioNTech vaccine candidate suggests is more efficacious than many had dared to expect. The announcement is a welcome indication that a safe and effective COVID-19 vaccine might be within reach, but there are…

Vaccination programmes have prevented millions of deaths worldwide, but their continued success relies on our continued participation.

With Denmark culling its entire farmed mink population following discovery of a mutated form of SARS-CoV2, are we at risk of further complications and diseases from animal-human transmission?

Superspreading events, where one person infects tens of others, appear to be playing an increasingly significant role in the spread of COVID-19. So what have we learned about these events and how can we stop them from fuelling the pandemic?

Anosmia is the medical term for a sudden loss of smell and has been associated with COVID-19. Here’s a closer look at the olfactory dysfunctions linked to the SARS-CoV-2 virus.

Effective treatments that are accessible to everyone who needs them have to be part of the solution to the coronavirus pandemic – here's why.

Malnutrition can affect the immune system and the quality of immune response to vaccinations, with potential implications for low-income countries where COVID-19 is already fuelling a "hunger pandemic" in the most vulnerable people.

Spending less time in the workplace usually results in lower rates of infectious disease, but workplace closures in Southeast Asia and the Western Pacific may be increasing exposure to the mosquitoes that transmit dengue virus.

Combining geographical information on populations, locations of health care sites, and the movement of vaccinators can offer insights into how efficient and equitable vaccination coverage is, and has great potential to improve immunisation…

Vaccines based on the common cold virus are at the forefront of the COVID-19 vaccine race, but they may be less effective in people who have previously been infected by these common pathogens. So how could we overcome this challenge?

Global Handwashing Day and the ongoing spread of COVID-19 is a timely reminder about the importance of handwashing with soap as an effective and affordable way to stay healthy.

People who have had COVID-19 can develop an immune response that normally protects people from recurrent infection. But now that reinfections of COVID-19 have been recorded, what does that mean for our ability to fight the virus?

Just over six months since COVID-19 was declared a pandemic, what do we know about this new coronavirus?

For more than 30 years, monoclonal antibodies have transformed the way we treat many diseases. Researchers think they are also one of the most promising treatments for Covid-19. Here's why.

Emergency use procedures are designed to make potentially life-saving medical products available as quickly as possible during health emergencies. A record number have been granted since the arrival of COVID-19 pandemic, but what does this mean…

The Covid-19 pandemic is a social and an economic crisis just as much as it is a health crisis – its repercussions, severe and far-reaching, are being felt across the world.

The UK is expected to host the world’s first COVID-19 human “challenge” trials, which will involve deliberately infecting healthy volunteers with coronavirus to assess the effectiveness of experimental vaccines. So far, around 2,000 potential…

Every winter, hundreds of thousands become infected with seasonal influenza, which kills between 290,000 and 650,000 people worldwide each year. But this year, we have another respiratory illness to contend with: COVID-19. So, what does this mean…

At the beginning of the pandemic there was a mad scramble to develop a test which would accurately diagnose COVID-19 infection. Now, six months in, hundreds of testsare available – but how do they differ, and which test is the most appropriate…

How will COVAX ensure that COVID-19 vaccine doses reach all countries at the same time, and protect those people that need it the most?

Effective vaccines prevent individuals from developing disease, but some also stop people transmitting the pathogens that cause them. What role will they have to play in ending the COVID-19 pandemic?

No one is safe until everyone is safe. This phrase has become a slogan for global health figures but what does it mean in the worldwide COVID-19 response?

As COVID-19 vaccines have a critical role to play in ending this pandemic crisis, many experts have described them as a global public good. But what exactly does that mean?

Many of the infections that can lead to sepsis are becoming resistant to antibiotics, which means that preventing them by vaccination is critical.

Antibodies are one route to immunity against disease, but T cells and innate immunity also play a crucial role in protecting us. So, how could these different types of immunity be mobilised against COVID-19

3 September 2020

COVAX explained

To end this global health crisis we don’t just need COVID-19 vaccines, we also need to ensure that everyone in the world has access to them.

When COVID-19 vaccines become available demand is likely to outstrip supply, at least initially. So, who should be first in line?

What do the first confirmed cases of reinfection with COVID-19 mean for the rest of us and future of this pandemic?

One of the most time-consuming parts of vaccine research and development is the testing of a vaccine. How does this work, and how, in the context of COVID-19, are scientists trying to speed it up?

Vaccines prevent millions of deaths every year by harnessing the body’s immune system to create defences against future infection. But how exactly does this work?

Since 2000, Gavi has been increasing equitable access to vaccines by working with the world’s poorest countries. Yet during a pandemic, more prosperous countries are also at risk of falling through the net. How will Gavi respond?

Lower-income countries are seeing better vaccination coverage than they have had in decades, but the COVID-19 pandemic is threatening to hamper progress.

While researchers racing to develop a COVID-19 vaccine, the potential of the BCG vaccine - used to prevent TB – to slow the pandemic has been hotly debated. New research suggesting that the BCG could prevent severe COVID-19 disease has made…

With surveys using antibody tests yielding disappointing results, there are growing concerns that fewer people may have already been infected with SARS-CoV-2 than was previously hoped. Yet antibodies are only part of our immune system’s response…

On 25 June, the outbreak of Ebola in the Democratic Republic of the Congo that has raged for more than 2 years is over. What does this mean for the country and what can it teach us about ending the COVID-19 pandemic?

At a time when economies are under pressure and government spending is under scrutiny, transparency and accountability within the development sector is more important than ever.

Beijing, a city month’s ahead of Europe in COVID-19 terms, is now plunging back into lockdown. Many are concerned that this could be the first hint of a second wave. But is that likely and what would it look like?

Even mild symptoms from the new coronavirus can last for weeks, or disappear only to rebound with renewed intensity, so what long-term effects does the disease have on our health?

With so many COVID-19 candidate vaccines in development, and with most of them likely to fail, what’s the best way for governments to ensure they back a winner and ensure there are enough doses for everyone?

A third of the world has been under some form of lockdown to tackle the COVID-19 pandemic, but has it made any difference to the number of cases and deaths?

Despite the devastating economic impact this pandemic has had on businesses across the world, many are doing their part to bring this crisis to an end.

As one of the poorest low-income countries in South East Asia, Myanmar faces many barriers to implementing a strong and effective response to COVID-19. Gavi has now allocated over US$ 8.8 million to help ensure that Myanmar is better able to…

The physical distancing necessary to slow the spread of COVID-19 can be emotionally distressing, but since the virus is unlikely to disappear soon, when will life regain a semblance of normality?

The pandemic will only strengthen our commitment to vaccinate vulnerable communities. On 4 June 2020 Gavi will hold its third donor pledging conference online with the aim to raise vital funds for the next five years.

The COVID-19 pandemic is most often compared to the H1N1 influenza pandemic of 1918, or Spanish flu, even though there have been three other major pandemics since then. So how does this coronavirus pandemic compare to those?

Black, Asian and minority ethnic (BAME) communities in Europe and the USA are overrepresented in COVID-19 deaths. In the bid to slow and, ultimately, stop the spread of COVID-19 it is vital to understand the reasons why, in order to adequately…

While the number of COVID-19 cases and deaths stays relatively low across Africa, Asia and Latin America compared with the rest of the world, the economic and social consequences are likely to reverberate for decades to come.

The COVID-19 pandemic is disrupting vaccination programmes across the world, but this could provide an opportunity to hasten the move to digital record-keeping systems.

Altering the ease with which the new coronavirus spreads in the population is critical to controlling the pandemic. The number of people infected by any single case - the R number – will be key. If the virus is able to infect more than one person…

It is clear that the search for COVID-19 vaccines is being fast-tracked like never before. In just a few months, we now have over 100 vaccine candidates in development, ten of which are being tested in clinical trials.

Controlling the pandemic demands a multi-pronged approach with other key methods like contact tracing to help stop the chain of transmission.

What our lives will look in the short to medium term future is uncertain, but what does seem clear is we won’t return to a pre-COVID-19 life any time soon. Here are three potential scenarios that infectious disease experts have sketched out for…

Initially, children seemed to be least affected by the new coronavirus. However, new evidence suggests that a small number might have a rare immune reaction to COVID-19, with some needing intensive care.

Personal protective equipment, or PPE, such as masks and gloves are becoming part of our daily lives, but what counts as effective PPE and what doesn’t?

Tracking who is infected is essential to controlling the transmission of contagious diseases. Could digital technology prove to be a game-changer for the current pandemic?

Because of vaccination, many deadly diseases are now preventable. But we still lack vaccines for other potentially lethal diseases that could spread to become pandemics like COVID-19. Here is a list of 10 diseases to watch.

Even when a COVID-19 vaccine is available, testing can help pinpoint populations who should be prioritised for immunisation.

How we can ensure that once a COVID-19 vaccine is available, it is accessible to everyone that needs it.

With so many lives and livelihoods at stake, when will the lockdowns end, and what will they look like across the world?

How exactly is the COVID-19 virus spread and will a mask protect me?

How does the benefit of stopping the spread of coronavirus weigh up against the risks from diseases such as measles?

Although there are guidelines on how long people should self-isolate when infected, the data on how long people remain contagious is not yet fully understood.

As we continue to encroach on the environment and erode natural habitats, the likelihood of other diseases like COVID-19 emerging to devastate the planet are high.

Large-scale testing for COVID-19 could help solve some of the mysteries surrounding the virus that are still puzzling scientists.

With nearly 550,000 people infected, almost 25,000 dead, and hundreds of millions in lockdown across the globe, the coronavirus pandemic has brought the world to a standstill. But what do we know about COVID-19 and what can we do to fight this…

The idea of herd immunity as the solution to the COVID-19 pandemic has triggered heated debate, but what is herd immunity and how does it work? 

With an increasing number of countries around the globe going into lockdown because of the COVID-19 pandemic, many people forced to stay home may be wondering why these measures are necessary, how long they will need to go on for and what it will…

On the most recent issue of The Bio Report podcast, Gavi's Aurélia Nguyen discusses COVID-19 vaccine development, the role of the Vaccine Alliance in stopping the pandemic, and shares lessons learned from the 2014 Ebola outbreak that may prove…

If COVID-19 epidemics are not controlled, 510,000 people could die in the UK and 2.2 million in the USA.

We touch countless objects every day, from house keys to our mobile phones. The virus that causes COVID-19 can last for anywhere from 30 minutes to several hours in the air (in the form of aerosol droplets) before drifting down onto surfaces,…

Clinical trials for vaccines can take 10-15 years and cost hundreds of millions of dollars, which is why pharmaceutical companies can be reluctant to start down that challenging road without a definite pay-off at the end. As the COVID-19 pandemic…

From travel restrictions to social distancing, what is the best way to stop a pandemic?

Subscribe to our newsletter